In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BeiGene Ltd.

www.beigene.com

Latest From BeiGene Ltd.

Merck Is Counting On Keytruda To Establish Its Anti-TIGIT Drug

Vibostolimab is less advanced than Roche’s competing tiragolumab, but Merck thinks the combo of its anti-TIGIT and Keytruda will offer a better therapeutic profile.

ASCO Clinical Trials

Gilead Partnership With Arcus Brings PD-1, TIGIT Assets To Its IO Portfolio

The 10-year partnership brings Arcus up-front funding with ample earnout opportunities, while Gilead gets extensive opt-in rights and an equity stake it can increase – and potentially a wholly owned dual checkpoint combination.

Deals ImmunoOncology

No Love From US: Senate Bill Deals Blow To Aspiring China Biotechs

In a bipartisan move, the US Senate is moving to impose new rules on companies - including those from China - seeking US initial public offerings, adding further uncertainty over such plans and further stoking trade tensions.

Policy & Regulation Financing

China-US Virus Showdown Creating Health Policy Uncertainties

China has stepped up its support for the World Health Organization just as the US is ratcheting up its criticism of both the global health body and China, as policy observers watch closely for any signs the tense bilateral relationship may spill over to the health sector.

China United States
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
    • Large Molecule
      • Antibodies
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • BeiGene (Beijing) Co. Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • BeiGene Ltd.
  • Senior Management
  • John V Oyler, CEO
    Howard Liang, PhD, CFO & Chief Strategy Officer
    Guillaume Vignon, PhD, SVP, Bus. Dev.
  • Contact Info
  • BeiGene Ltd.
    Phone: 10 851 48500
    No. 30 Science Park Rd. Zhong-Guan-Cun
    Life Science Pk
    Changping District, 102206
    China
UsernamePublicRestriction

Register